TRPA1 antagonists for pain relief
A Koivisto, N Jalava, M Rantanen, H Chapman… - TRP Channels as …, 2024 - Elsevier
The topic of this chapter, transient receptor potential ankyrin 1 (TRPA1), is a calcium-
permeable nonselective cation channel that is a member of the TRP family expressed on …
permeable nonselective cation channel that is a member of the TRP family expressed on …
Medium-chain lipid conjugation facilitates cell-permeability and bioactivity
The majority of bioactive molecules act on membrane proteins or intracellular targets and
therefore needs to partition into or cross biological membranes. Natural products often …
therefore needs to partition into or cross biological membranes. Natural products often …
Fluorine-containing prolines: Synthetic strategies, applications, and opportunities
PK Mykhailiuk - The Journal of Organic Chemistry, 2022 - ACS Publications
Fluorinated prolines play an important role in peptide studies, protein engineering,
medicinal chemistry, drug discovery, and agrochemistry. Since the first synthesis of 4 …
medicinal chemistry, drug discovery, and agrochemistry. Since the first synthesis of 4 …
Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory …
JA Terrett, JQ Ly, P Katavolos… - Journal of Medicinal …, 2024 - ACS Publications
Transient receptor potential ankyrin 1 (TRPA1) is a nonselective calcium ion channel highly
expressed in the primary sensory neurons, functioning as a polymodal sensor for …
expressed in the primary sensory neurons, functioning as a polymodal sensor for …
Development of an amorphous solid dispersion formulation for mitigating mechanical instability of crystalline form and improving bioavailability for early phase clinical …
In this work, an amorphous solid dispersion (ASD) formulation was systematically developed
to simultaneously enhance bioavailability and mitigate the mechanical instability risk of the …
to simultaneously enhance bioavailability and mitigate the mechanical instability risk of the …
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease
AJ Roecker, KM Schirripa, HM Loughran… - ACS Medicinal …, 2023 - ACS Publications
Parkinson's disease is the second most prevalent progressive neurodegenerative disorder
characterized by the loss of dopaminergic neurons in the substantia nigra. Loss-of-function …
characterized by the loss of dopaminergic neurons in the substantia nigra. Loss-of-function …
Photosensitive and photoswitchable TRPA1 agonists optically control pain through channel desensitization
Z Qiao, J Luo, YQ Tang, Q Zhou, H Qi… - Journal of Medicinal …, 2021 - ACS Publications
Transient receptor potential ankyrin 1 (TRPA1) channel, as a nonselective ligand-gated
cation channel robustly in dorsal root ganglion sensory neurons, is implicated in sensing …
cation channel robustly in dorsal root ganglion sensory neurons, is implicated in sensing …
Allosteric modulation of α1β3γ2 GABAA receptors by farnesol through the neurosteroid sites
In mammalian cells, all-trans farnesol, a 15-carbon isoprenol, is a product of the mevalonate
pathway. It is the natural substrate of alcohol dehydrogenase and a substrate for CYP2E1 …
pathway. It is the natural substrate of alcohol dehydrogenase and a substrate for CYP2E1 …
Membrane lipids are an integral part of transmembrane allosteric sites in GPCRs: A case study of cannabinoid CB1 receptor bound to a negative allosteric modulator …
A growing number of G-protein-coupled receptor (GPCR) structures reveal novel
transmembrane lipid-exposed allosteric sites. Ligands must first partition into the …
transmembrane lipid-exposed allosteric sites. Ligands must first partition into the …
Development of a First-Generation Stereocontrolled Manufacturing Process of TRPA1 Inhibitor GDC-6599
AY Hong, KA Piechowicz, JC Timmerman… - … Process Research & …, 2024 - ACS Publications
We report a fit-for-purpose, stereocontrolled, and chromatography-free first-generation
manufacturing process for GDC-6599 (1), a TRPA1 inhibitor, to enable first-in-human clinical …
manufacturing process for GDC-6599 (1), a TRPA1 inhibitor, to enable first-in-human clinical …